Cwm LLC Grows Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Cwm LLC grew its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 178.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 577 shares of the biotechnology company’s stock after acquiring an additional 370 shares during the quarter. Cwm LLC’s holdings in Sarepta Therapeutics were worth $56,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Montag A & Associates Inc. purchased a new position in Sarepta Therapeutics in the 3rd quarter valued at about $30,000. Cary Street Partners Investment Advisory LLC grew its stake in Sarepta Therapeutics by 154.0% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 154 shares during the period. Fifth Third Bancorp raised its holdings in Sarepta Therapeutics by 1,215.8% in the 4th quarter. Fifth Third Bancorp now owns 1,000 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 924 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Sarepta Therapeutics by 96.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,397 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 1,176 shares during the period. Finally, Handelsinvest Investeringsforvaltning acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $302,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on SRPT shares. Mizuho increased their target price on Sarepta Therapeutics from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Barclays upped their price target on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. BMO Capital Markets assumed coverage on shares of Sarepta Therapeutics in a report on Wednesday, January 31st. They issued an “outperform” rating and a $170.00 price target on the stock. Cantor Fitzgerald restated a “neutral” rating and set a $128.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, May 2nd. Finally, Wedbush reiterated an “outperform” rating and issued a $224.00 target price on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $160.60.

Insider Activity

In related news, insider Bilal Arif sold 2,000 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the transaction, the insider now owns 26,836 shares in the company, valued at $3,457,550.24. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the transaction, the director now directly owns 7,516 shares in the company, valued at approximately $923,941.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Bilal Arif sold 2,000 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the completion of the sale, the insider now directly owns 26,836 shares of the company’s stock, valued at approximately $3,457,550.24. The disclosure for this sale can be found here. Insiders sold 25,731 shares of company stock worth $3,248,319 over the last ninety days. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Down 2.5 %

NASDAQ SRPT opened at $132.58 on Thursday. The stock has a market cap of $12.53 billion, a PE ratio of 1,205.27 and a beta of 0.95. The business has a 50 day moving average price of $125.37 and a two-hundred day moving average price of $111.22. Sarepta Therapeutics, Inc. has a fifty-two week low of $55.25 and a fifty-two week high of $159.89. The company has a quick ratio of 3.44, a current ratio of 4.05 and a debt-to-equity ratio of 1.18.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.84. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The business had revenue of $413.50 million during the quarter, compared to the consensus estimate of $375.52 million. During the same period in the prior year, the firm earned ($1.44) earnings per share. The business’s quarterly revenue was up 63.1% compared to the same quarter last year. As a group, sell-side analysts predict that Sarepta Therapeutics, Inc. will post 2.23 EPS for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.